Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector

使用自失活 (SIN) 伽马逆转录病毒载体进行 SCID-X1 基因治疗

基本信息

  • 批准号:
    8719920
  • 负责人:
  • 金额:
    $ 60.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Severe combined immunodeficiencies (SCID) are a heterogeneous group of fatal inherited disorders characterized by a profound reduction or absence of T lymphocyte function. The most common form of SCID is an X-linked form (SCID-X1) caused by defects in the common cytokine receptor ? chain (?c or IL-2RG). Until the recent advent of somatic gene therapy, hematopoietic stem cell transplantation (HSCT) offered the only curative option for patients with any form of SCID. In the 20-25% of cases when a genotypically matched sibling donor is available, HSCT is a highly successful procedure. For the remaining individuals, alternative donor transplants, principally from matched unrelated (MUD) or haploidentical parental donors have been problematic due to toxicity from ablative therapy, graft-versus-host disease and incomplete lymphoid reconstitution. Recent gene transfer trials have documented efficacy, albeit with toxicity related to insertional mutagenesis. We have developed a next generation self-inactivating (SIN) vector expressing the IL-2RG gene controlled by an internal cellular promoter, pSRS11.EFS.IL2RG.pre* and have shown this vector to have reduced mutagenic potential compared to LTR configuration in non-clinical studies. We hypothesize that this vector will have similar efficacy to the vector used in the past trial but without insertional mutagenesis. The current study is a phase l/ll trial of somatic gene therapy for patients with SCID-X1. Inclusion criteria include patients with a definitive diagnosis of SCIDX1 in whom HLA-matched family donors are unavailable and who are either patients >3.5 months old and lack an HLA identical (A,B,C,DR,DQ) unrelated donor OR patients of any age with an active, therapy-resistant infection or other medical conditions that significantly increase the risk of allogeneic transplant. Primary endpoints include immunological reconstitution defined as absolute CD3 cells of >300/¿l and PHA stimulation index >15 at 6 months post infusion and the incidence of life-threatening adverse reactions related to the gene transfer procedure. We will also perform detailed immune reconstitution and insertion site analysis studies.
描述(由申请人提供):严重联合免疫缺陷(SCID)是一组不同类型的致命性遗传性疾病,其特征是T淋巴细胞功能严重降低或缺失。SCID最常见的形式是X连锁形式(SCID-X1),由常见的细胞因子受体缺陷引起。链(?C或IL-2RG)。直到最近躯体基因治疗的出现,造血干细胞移植(HSCT)为任何形式的SCID患者提供了唯一的治疗选择。在20%-25%的病例中,当有基因匹配的同胞供体时,HSCT是一种非常成功的手术。对于其余个体,替代供者移植,主要来自匹配的无血缘关系(MUD)或单倍体相合的双亲供者,由于消融治疗、移植物抗宿主病和不完全淋巴重建的毒性而一直存在问题。最近的基因转移试验已经证明了有效性,尽管与插入突变有关的毒性。我们已经开发了一种由内部细胞启动子pSRS11.EFS.IL2RG.pre*控制的表达IL-2RG基因的新一代自失活(SIN)载体,并在非临床研究中表明该载体与LTR配置相比具有更低的诱变潜力。我们假设该载体将具有与过去试验中使用的载体类似的效果,但没有插入突变。本研究是针对SCID-X1患者的体细胞基因治疗的L/11期试验。纳入标准包括确诊为SCIDX1的患者,其中没有匹配的家庭捐赠者,并且是3.5个月大的患者和缺乏完全相同的(A,B,C,DR,DQ)无关捐赠者的患者,或者任何年龄的患者,他们患有活动性的、耐药感染或其他显著增加异基因移植风险的医疗条件。主要观察指标包括输注后6个月的免疫重建(定义为L体内CD3细胞的绝对值)和PHA刺激指数及与基因转移相关的危及生命的不良反应的发生率。我们还将进行详细的免疫重建和插入部位分析研究。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
影响用于治疗 X 连锁严重联合免疫缺陷的自失活 γ-逆转录病毒载体的临床级生产的关键变量。
  • DOI:
    10.1038/gt.2012.37
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
    vanderLoo,JCM;Swaney,WP;Grassman,E;Terwilliger,A;Higashimoto,T;Schambach,A;Hacein-Bey-Abina,S;Nordling,DL;Cavazzana-Calvo,M;Thrasher,AJ;Williams,DA;Reeves,L;Malik,P
  • 通讯作者:
    Malik,P
Curing genetic disease with gene therapy.
通过基因疗法治愈遗传病。
Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.
  • DOI:
    10.1038/gt.2011.102
  • 发表时间:
    2012-03
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A WILLIAMS其他文献

DAVID A WILLIAMS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A WILLIAMS', 18)}}的其他基金

The role of Septin6 Group in Murine and Human Hematopoiesis
Septin6 组在小鼠和人类造血中的作用
  • 批准号:
    10718515
  • 财政年份:
    2023
  • 资助金额:
    $ 60.81万
  • 项目类别:
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
靶向 BCL11A 的基因疗法可诱导胎儿血红蛋白并降低镰状细胞病患者的镰状血红蛋白
  • 批准号:
    10083551
  • 财政年份:
    2020
  • 资助金额:
    $ 60.81万
  • 项目类别:
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
靶向 BCL11A 的基因疗法可诱导胎儿血红蛋白并降低镰状细胞病患者的镰状血红蛋白
  • 批准号:
    10179447
  • 财政年份:
    2017
  • 资助金额:
    $ 60.81万
  • 项目类别:
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
靶向 BCL11A 的基因疗法可诱导胎儿血红蛋白并降低镰状细胞病患者的镰状血红蛋白
  • 批准号:
    9363943
  • 财政年份:
    2017
  • 资助金额:
    $ 60.81万
  • 项目类别:
ConProject-005
ConProject-005
  • 批准号:
    10594167
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
ConProject-006
ConProject-006
  • 批准号:
    10609202
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
Gene Therapy for SCID-X1 with Low Dose Busulfan and a SIN-lentiviral Vector
使用低剂量白消安和 SIN 慢病毒载体对 SCID-X1 进行基因治疗
  • 批准号:
    10827632
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
ConProject-003
ConProject-003
  • 批准号:
    10594165
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
Development of novel selective Rac inhibitors for refractory leukemias
开发治疗难治性白血病的新型选择性 Rac 抑制剂
  • 批准号:
    9176356
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector
使用低剂量白消安和 SIN 慢病毒载体对 SCID-X1 进行基因治疗
  • 批准号:
    10207386
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:

相似海外基金

A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
  • 批准号:
    MR/X00094X/1
  • 财政年份:
    2022
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Research Grant
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
  • 批准号:
    22K15910
  • 财政年份:
    2022
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
  • 批准号:
    22K06738
  • 财政年份:
    2022
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
  • 批准号:
    19K17779
  • 财政年份:
    2019
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
  • 批准号:
    18K00267
  • 财政年份:
    2018
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
  • 批准号:
    379425
  • 财政年份:
    2018
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
  • 批准号:
    9576448
  • 财政年份:
    2017
  • 资助金额:
    $ 60.81万
  • 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
  • 批准号:
    16K15156
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
  • 批准号:
    367156
  • 财政年份:
    2016
  • 资助金额:
    $ 60.81万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了